CRISPR-Cas9 genome editing for cancer immunotherapy: opportunities and challenges
The DOI matches its Crossref record; 63 of the 65 references it cites were found in a registry or an index.
Abstract
Cancer immunotherapy, consisting of antibodies, adoptive T-cell transfer, vaccines and cytokines, is a novel strategy for fighting cancer by artificially stimulating the immune system. It has developed rapidly in recent years, and its efficacy in hematological malignancies and solid tumors has been remarkable. It is regarded as one of the most promising methods for cancer therapy. The current trend in immunotherapy research seeks to improve its efficacy and to ensure the safety of cancer immunotherapy through the use of gene editing technologies. As it is an efficient and simple technology, the CRISPR-Cas9 system is highly anticipated to dramatically strengthen cancer immunotherapy. Intensive research on the CRISPR-Cas9 system has provided increasing confidence to clinicians that this system can be put into clinical use in the near future. This paper reviews the application and challenges of CRISPR-Cas9 in this field, based on various strategies including adaptive cell therapy and antibody therapy, and also highlights the function of CRISPR/Cas9 in the screening of new cancer targets.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“Xia, 2019, Applications and advances of CRISPR-Cas9 in cancer immunotherapy, J Med Genet, 56, 4, 10.1136/jmedgenet-2018-105422”
Cited work 10.1136/jmedgenet-2018-105422 · retracted 2026-04-14 · notice 10.1136/jmg-2026-56-1-2019ret · this paper published 2019-12-02
Citations
Cites
1 retracted
Retracted: Applications and advances of CRISPR-Cas9 in cancer immunotherapy
Xia, A., He, Q., Wang, J., Zhu, J., Sha, Y., Sun, B., & Lu, X. (2018) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2018-105422 · Cited by 61
RetractedDevelopment and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
Genome-scale CRISPR-Cas9 knockout screening in human cells
Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., et al. (2014) · Science · doi:10.1126/science.1247005 · Cited by 5,234
High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects
Kleinstiver, B. P., Pattanayak, V., Prew, M. S., Tsai, S. Q., Nguyen, N. T., Zheng, Z., & Joung, J. K. (2016) · Nature · doi:10.1038/nature16526 · Cited by 2,673
Chimeric Antigen Receptor Therapy
June, C. H., & Sadelain, M. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1706169 · Cited by 2,331
Scott, A. M., Wolchok, J. D., & Old, L. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3236 · Cited by 2,160
CRISPR-Cas9 Knockin Mice for Genome Editing and Cancer Modeling
Platt, R. J., Chen, S., Zhou, Y., Yim, M. J., Swiech, L., Kempton, H. R., Dahlman, J. E., Parnas, O., Eisenhaure, T. M., Jovanovic, M., et al. (2014) · Cell · doi:10.1016/j.cell.2014.09.014 · Cited by 2,001
Self-citationKim, S., Kim, D., Cho, S. W., Kim, J., & Kim, J.-S. (2014) · Genome Research · doi:10.1101/gr.171322.113 · Cited by 1,856
Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
Eyquem, J., Mansilla-Soto, J., Giavridis, T., van der Stegen, S. J. C., Hamieh, M., Cunanan, K. M., Odak, A., Gönen, M., & Sadelain, M. (2017) · Nature · doi:10.1038/nature21405 · Cited by 1,831
High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities.
Hart, T., Chandrashekhar, M., Aregger, M., Steinhart, Z., Brown, K. R., MacLeod, G., Mis, M., Zimmermann, M., Fradet-Turcotte, A., Sun, S., et al. (2015) · Cell · doi:10.1016/j.cell.2015.11.015 · Cited by 1,571
Norelli, M., Camisa, B., Barbiera, G., Falcone, L., Purevdorj, A., Genua, M., Sanvito, F., Ponzoni, M., Doglioni, C., Cristofori, P., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0036-4 · Cited by 1,406
Gene Editing of CCR5 in Autologous CD4 T Cells of Persons Infected with HIV
Tebas, P., Stein, D., Tang, W. W., Frank, I., Wang, S. Q., Lee, G., Spratt, S. K., Surosky, R. T., Giedlin, M. A., Nichol, G., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300662 · Cited by 1,357
CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade
Giavridis, T., van der Stegen, S. J. C., Eyquem, J., Hamieh, M., Piersigilli, A., & Sadelain, M. (2018) · Nature Medicine · doi:10.1038/s41591-018-0041-7 · Cited by 1,272
CRISPR–Cas9 genome editing induces a p53-mediated DNA damage response
Haapaniemi, E., Botla, S., Persson, J., Schmierer, B., & Taipale, J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0049-z · Cited by 1,264
In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target
Manguso, R. T., Pope, H. W., Zimmer, M. D., Brown, F. D., Yates, K. B., Miller, B. C., Collins, N. B., Bi, K., LaFleur, M. W., Juneja, V. R., et al. (2017) · Nature · doi:10.1038/nature23270 · Cited by 1,147
Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells
Hendel, A., Bak, R. O., Clark, J. T., Kennedy, A. B., Ryan, D. E., Roy, S., Steinfeld, I., Lunstad, B. D., Kaiser, R. J., Wilkens, A. B., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3290 · Cited by 1,090
p53 inhibits CRISPR–Cas9 engineering in human pluripotent stem cells
Ihry, R. J., Worringer, K. A., Salick, M. R., Frias, E., Ho, D., Theriault, K., Kommineni, S., Chen, J., Sondey, M., Ye, C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0050-6 · Cited by 978
Mechanisms of resistance to CAR T cell therapy
Shah, N. N., & Fry, T. J. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0184-6 · Cited by 959
Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition
Ren, J., Liu, X., Fang, C., Jiang, S., June, C. H., & Zhao, Y. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1300 · Cited by 942
Santomasso, B. D., Park, J. H., Salloum, D., Riviere, I., Flynn, J., Mead, E., Halton, E., Wang, X., Senechal, B., Purdon, T., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1319 · Cited by 942
Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells
Fraietta, J. A., Nobles, C. L., Sammons, M. A., Lundh, S., Carty, S. A., Reich, T. J., Cogdill, A. P., Morrissette, J. J. D., DeNizio, J. E., Reddy, S., et al. (2018) · Nature · doi:10.1038/s41586-018-0178-z · Cited by 862
Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains
Shi, J., Wang, E., Milazzo, J. P., Wang, Z., Kinney, J. B., & Vakoc, C. R. (2015) · Nature Biotechnology · doi:10.1038/nbt.3235 · Cited by 761
Rupp, L. J., Schumann, K., Roybal, K. T., Gate, R. E., Ye, C. J., Lim, W. A., & Marson, A. (2017) · Scientific Reports · doi:10.1038/s41598-017-00462-8 · Cited by 757
Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses
Cho, J. H., Collins, J. J., & Wong, W. W. (2018) · Cell · doi:10.1016/j.cell.2018.03.038 · Cited by 682
Transcriptome-wide off-target RNA editing induced by CRISPR-guided DNA base editors
Grünewald, J., Zhou, R., Garcia, S. P., Iyer, S., Lareau, C. A., Aryee, M. J., & Joung, J. K. (2019) · Nature · doi:10.1038/s41586-019-1161-z · Cited by 663
Poirot, L., Philip, B., Schiffer-Mannioui, C., Le Clerre, D., Chion-Sotinel, I., Derniame, S., Potrel, P., Bas, C., Lemaire, L., Galetto, R., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3321 · Cited by 605
Zhang, C., Liu, J., Zhong, J. F., & Zhang, X. (2017) · Biomarker Research · doi:10.1186/s40364-017-0102-y · Cited by 578
Immune suppressive mechanisms in the tumor microenvironment
Munn, D. H., & Bronte, V. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.10.009 · Cited by 519
Expanding the genetic editing tool kit: ZFNs, TALENs, and CRISPR-Cas9
Gupta, R. M., & Musunuru, K. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72992 · Cited by 492
CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies
Gomes-Silva, D., Srinivasan, M., Sharma, S., Lee, C. M., Wagner, D. L., Davis, T. H., Rouce, R. H., Bao, G., Brenner, M. K., & Mamonkin, M. (2017) · Blood · doi:10.1182/blood-2017-01-761320 · Cited by 462
CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells
Liu, X., Zhang, Y., Cheng, C., Cheng, A. W., Zhang, X., Li, N., Xia, C., Wei, X., Liu, X., & Wang, H. (2017) · Cell Research · doi:10.1038/cr.2016.142 · Cited by 396
An “off-the-shelf” fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies
Cooper, M. L., Choi, J., Staser, K., Ritchey, J. K., Devenport, J. M., Eckardt, K., Rettig, M. P., Wang, B., Eissenberg, L. G., Ghobadi, A., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0065-5 · Cited by 392
DNA methyltransferases and their roles in tumorigenesis
Zhang, W., & Xu, J. (2017) · Biomarker Research · doi:10.1186/s40364-017-0081-z · Cited by 382
Self-citationCRISPR gene-editing tested in a person for the first time
Cyranoski, D. (2016) · Nature · doi:10.1038/nature.2016.20988 · Cited by 362
Rab29 activation of the Parkinson's disease‐associated LRRK2 kinase
Purlyte, E., Dhekne, H. S., Sarhan, A. R., Gomez, R., Lis, P., Wightman, M., Martinez, T. N., Tonelli, F., Pfeffer, S. R., & Alessi, D. R. (2018) · The EMBO Journal · doi:10.15252/embj.201798099 · Cited by 336
Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy
Beavis, P. A., Henderson, M. A., Giuffrida, L., Mills, J. K., Sek, K., Cross, R. S., Davenport, A. J., John, L. B., Mardiana, S., Slaney, C. Y., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci89455 · Cited by 325
Refining strategies to translate genome editing to the clinic
Cornu, T. I., Mussolino, C., & Cathomen, T. (2017) · Nature Medicine · doi:10.1038/nm.4313 · Cited by 252
Mixed T cell receptor dimers harbor potentially harmful neoreactivity
van Loenen, M. M., de Boer, R., Amir, A. L., Hagedoorn, R. S., Volbeda, G. L., Willemze, R., van Rood, J. J., Falkenburg, J. H. F., & Heemskerk, M. H. M. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1005802107 · Cited by 232
CRISPR-mediated TCR replacement generates superior anticancer transgenic T cells
Legut, M., Dolton, G., Mian, A. A., Ottmann, O. G., & Sewell, A. K. (2018) · Blood · doi:10.1182/blood-2017-05-787598 · Cited by 228
CRISPR/Cas9-Mediated Knockout of DGK Improves Antitumor Activities of Human T Cells
Jung, I.-Y., Kim, Y.-Y., Yu, H.-S., Lee, M., Kim, S., & Lee, J. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0030 · Cited by 222
Evaluation of TCR Gene Editing Achieved by TALENs, CRISPR/Cas9, and megaTAL Nucleases
Osborn, M. J., Webber, B. R., Knipping, F., Lonetree, C.-L., Tennis, N., DeFeo, A. P., McElroy, A. N., Starker, C. G., Lee, C., Merkel, S., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2015.197 · Cited by 201
A chemical-inducible CRISPR–Cas9 system for rapid control of genome editing
Liu, K. I., Ramli, M. N. B., Woo, C. W. A., Wang, Y., Zhao, T., Zhang, X., Yim, G. R. D., Chong, B. Y., Gowher, A., Chua, M. Z. H., et al. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2179 · Cited by 197
A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy
Zhang, E., & Xu, H. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0379-6 · Cited by 194
Fas–Fas Ligand: Checkpoint of T Cell Functions in Multiple Sclerosis
Volpe, E., Sambucci, M., Battistini, L., & Borsellino, G. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00382 · Cited by 185
Driving T-cell immunotherapy to solid tumors
Garber, K. (2018) · Nature Biotechnology · doi:10.1038/nbt.4090 · Cited by 159
Merkle, F. T., Neuhausser, W. M., Santos, D., Valen, E., Gagnon, J. A., Maas, K., Sandoe, J., Schier, A. F., & Eggan, K. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.04.007 · Cited by 152
CD3 limits the efficacy of TCR gene therapy in vivo
Ahmadi, M., King, J. W., Xue, S.-A., Voisine, C., Holler, A., Wright, G. P., Waxman, J., Morris, E., & Stauss, H. J. (2011) · Blood · doi:10.1182/blood-2011-04-346338 · Cited by 116
Advancing chimeric antigen receptor T cell therapy with CRISPR/Cas9
Ren, J., & Zhao, Y. (2017) · Protein & Cell · doi:10.1007/s13238-017-0410-x · Cited by 98
Wang, L., Nanayakkara, G., Yang, Q., Tan, H., Drummer, C., Sun, Y., Shao, Y., Fu, H., Cueto, R., Shan, H., et al. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0526-8 · Cited by 97
Stromnes, I. M., Blattman, J. N., Tan, X., Jeevanjee, S., Gu, H., & Greenberg, P. D. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41991 · Cited by 85
Mason, D. M., Weber, C. R., Parola, C., Meng, S. M., Greiff, V., Kelton, W. J., & Reddy, S. T. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky550 · Cited by 84
Editing of mouse and human immunoglobulin genes by CRISPR-Cas9 system
Cheong, T.-C., Compagno, M., & Chiarle, R. (2016) · Nature Communications · doi:10.1038/ncomms10934 · Cited by 80
Zhou, X., Updegraff, B. L., Guo, Y., Peyton, M., Girard, L., Larsen, J. E., Xie, X.-J., Zhou, Y., Hwang, T. H., Xie, Y., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-1267-t · Cited by 78
Self-citationChan, K. F., Shahreel, W., Wan, C., Teo, G., Hayati, N., Tay, S. J., Tong, W. H., Yang, Y., Rudd, P. M., Zhang, P., et al. (2016) · Biotechnology Journal · doi:10.1002/biot.201500331 · Cited by 68
Presotto, D., Erdes, E., Duong, M. N., Allard, M., Regamey, P.-O., Quadroni, M., Doucey, M.-A., Rufer, N., & Hebeisen, M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01564 · Cited by 63
CRISPR/Cas9 genome editing: Fueling the revolution in cancer immunotherapy
Liu, X., & Zhao, Y. (2018) · Current Research in Translational Medicine · doi:10.1016/j.retram.2018.04.003 · Cited by 60
Suicide Gene Therapy to Increase the Safety of Chimeric Antigen Receptor-Redirected T Lymphocytes
Casucci, M., & Bondanza, A. (2011) · Journal of Cancer · doi:10.7150/jca.2.378 · Cited by 52
One‐step CRISPR/Cas9 method for the rapid generation of human antibody heavy chain knock‐in mice
Lin, Y., Pecetta, S., Steichen, J. M., Kratochvil, S., Melzi, E., Arnold, J., Dougan, S. K., Wu, L., Kirsch, K. H., Nair, U., et al. (2018) · The EMBO Journal · doi:10.15252/embj.201899243 · Cited by 46
Molecular engineering of antibodies for site-specific covalent conjugation using CRISPR/Cas9
Khoshnejad, M., Brenner, J. S., Motley, W., Parhiz, H., Greineder, C. F., Villa, C. H., Marcos-Contreras, O. A., Tsourkas, A., & Muzykantov, V. R. (2018) · Scientific Reports · doi:10.1038/s41598-018-19784-2 · Cited by 36
Shao, H., Zhang, W., Hu, Q., Wu, F., Shen, H., & Huang, S. (2010) · Molecular Biology Reports · doi:10.1007/s11033-010-0053-y · Cited by 26
(2016) · Nature Biotechnology · doi:10.1038/nbt0816-796a · Cited by 7
Synthetic human genome set to spur applications
Dance, A. (2016) · Nature Biotechnology · doi:10.1038/nbt0816-796b · Cited by 5
Abstract LB-187: New methods for controlling CAR T cell-mediated cytokine storms
Lee, Y. G., Chu, H., & Low, P. S. (2017) · Cancer Research · doi:10.1158/1538-7445.am2017-lb-187 · Cited by 2
Cited by
Using Gene Editing Approaches to Fine-Tune the Immune System
Pavlovic, K., Tristán‐Manzano, M., Maldonado‐Pérez, N., Cortijo-Gutierréz, M., Sánchez-Hernández, S., Justicia-Lirio, P., Carmona-Luque, M. D., Herrera, C., Martín, F., & Benabdellah, K. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.570672 · Cited by 54
Nanoparticles for Cancer Immunotherapy: Innovations and Challenges
Fallatah, M., Alradwan, I. A., Fayez, N. A., Aodah, A. H., Alkhrayef, M. N., Majrashi, M. A., & Jamous, Y. F. (2025) · Pharmaceuticals · doi:10.3390/ph18081086 · Cited by 56
“Addressing these hurdles is essential to fully realize its therapeutic potential and translate these innovations into safe and effective clinical applications [248].”
Hosseini, S. A., Jouneghani, A. S., Ghatrehsamani, M., Yaghoobi, H., Elahian, F., & Mirzaei, S. A. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.11.018 · Cited by 29
CRISPR/Cas9: an overview of recent developments and applications in cancer research
Devi, S. N., Rana, R., Malik, P., & Ganguly, N. K. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000001081 · Cited by 17
“Preclinical studies show PD-1 knockout CAR-T cells improve persistence and tumor clearance in mouse models [60] .”
BackgroundZhi, L., Su, X., Yin, M., Zhang, Z., Lü, H., Niu, Z., Guo, C., Zhu, W., & Zhang, X. (2021) · Cellular Immunology · doi:10.1016/j.cellimm.2021.104436 · Cited by 15
Metadata
- Authors
- Chen, M., Xu, J., Zhou, Y., Zhang, S., & Zhu, D.
- Affiliations
- Bengbu Medical College (CN)
- Department of Rehabilitation, Huai'an Second People's Hospital, The Affiliated Huai'an Hospital of Xuzhou Medical University, Huai'an, China, 223001
- Fudan University (CN)
- Renmin Hospital of Wuhan University (CN)
- Corresponding author
- Zhang, Silin
- Zhu, Di
- Venue
- Briefings in Functional Genomics
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-12-02
- Volume
- 19
- Issue
- 3
- Pages
- 183-190
- ISSN
- 2041-2647 (ISSN-L)
- 2041-2657
- OpenAlex
- W2992262155
- Cited by
- 12
- References
- 65
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 3 · 2022: 1 · 2021: 1 · 2020: 2
- FWCI
- 0.33
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Briefings in Functional Genomics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Project on Joint Translational Research of the School of Pharmacy and Minhang Hospital (RO-MY201712)
- National Natural Science Foundation of China (81872895)
- Projects on Science and Technology Commission of Shanghai (18ZR1403900)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Keywords
- CRISPR/Cas9, genome editing, cancer immunotherapy, adoptive T cell therapy, antibody therapy, cancer vaccines, cytokines, hematologic malignancies, solid tumors, gene editing safety
- MeSH terms
- Gene Editing, Humans, Immunotherapy, Neoplasms, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.